Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Abstract

BRCA2-associated breast cancer is more sensitive to standard first-line chemotherapy for metastatic breast cancer in comparison with sporadic breast cancer, especially to anthracyclines. For BRCA1-associated breast cancer no statistically significant higher sensitivity was observed.